<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37343193</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1559-2308</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Epigenetics</Title><ISOAbbreviation>Epigenetics</ISOAbbreviation></Journal><ArticleTitle>LncRNA <i>NEAT1</i> promotes IL-6 secretion in monocyte-derived dendritic cells via sponging <i>miR-365a-3p</i> in systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>2226492</StartPage><MedlinePgn>2226492</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2226492</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/15592294.2023.2226492</ELocationID><Abstract><AbstractText>Increasing evidence has uncovered the essential roles of long noncoding RNAs (lncRNAs) in biological and pathological functions of dendritic cells (DCs) among patients with systemic lupus erythematosus (SLE). However, whether lncRNA nuclear paraspeckle assembly transcript 1 (<i>NEAT1</i>) could modulate DCs, especially in the inflammation of SLE, remains largely unknown. Fifteen SLE patients and fifteen age-matched healthy controls were included, and their monocyte-derived dendritic cells (moDCs) were cultured in vitro. Our research identified that the expression of <i>NEAT1</i> was significantly increased in moDCs of SLE patients and positively correlated with disease activity. Interleukin 6 (IL-6) from both plasma and secreted supernatants of moDCs was also elevated in the SLE group. In addition, regulation of <i>NEAT1</i> in moDCs by transfection could lead to the corresponding change in IL-6 generation. While for <i>miR-365a-3p</i>, a micro-RNA that can bind with the 3' UTR region of <i>IL6</i> and <i>NEAT1</i>, it may serve as a negative modulator since its overexpression could result in the reduction of IL-6 levels and vice versa. Additionally, the elevation in <i>NEAT1</i> expression could increase the secretion of IL-6 by specifically binding to <i>miR-365a-3p</i>, reducing the negative modulatory effects of <i>miR-365a-3p</i> on the <i>IL6</i> target gene, which suggested that elevated <i>NEAT1</i> expression could function as the competing endogenous RNA (ceRNA). In conclusion, our findings indicate that <i>NEAT1</i> can efficiently sponge <i>miR-365a-3p</i> to upregulate expression and secretion of IL-6 in moDCs, suggesting that the <i>NEAT1/miR-365a-3p/IL6</i> axis may be involved in the development of SLE disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Mengmeng</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6752-4827</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yilun</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0584-5083</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-8201-2774</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9449-7593</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Zhanyan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5318-4323</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jinhua</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2725-4903</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Dermatology, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Epigenetics</MedlineTA><NlmUniqueID>101265293</NlmUniqueID><ISSNLinking>1559-2294</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C546819">MIRN365 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577276">NEAT1 long non-coding RNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062085" MajorTopicYN="Y">RNA, Long Noncoding</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">ceRNA</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">interleukin 6</Keyword><Keyword MajorTopicYN="N">long non-coding RNA</Keyword><Keyword MajorTopicYN="N">monocyte-derived dendritic cells</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>21</Day><Hour>19</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>21</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37343193</ArticleId><ArticleId IdType="pmc">PMC10286691</ArticleId><ArticleId IdType="doi">10.1080/15592294.2023.2226492</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tian J, Zhang D, Yao X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82(3):351&#x2013;12. doi:10.1136/ard-2022-223035</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-223035</ArticleId><ArticleId IdType="pmc">PMC9933169</ArticleId><ArticleId IdType="pubmed">36241363</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees F, Doherty M, Grainge MJ, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology. 2017;56(11):1945&#x2013;1961. doi:10.1093/rheumatology/kex260</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex260</ArticleId><ArticleId IdType="pubmed">28968809</ArticleId></ArticleIdList></Reference><Reference><Citation>Melander C, Sall&#xe9;e M, Trolliet P, et al. Rituximab in severe lupus nephritis: early b-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol. 2009;4(3):579&#x2013;587. doi:10.2215/CJN.04030808</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.04030808</ArticleId><ArticleId IdType="pmc">PMC2653670</ArticleId><ArticleId IdType="pubmed">19261822</ArticleId></ArticleIdList></Reference><Reference><Citation>Liossis S-N, Staveri C.. B cell-based treatments in SLE: past experience and current directions. Curr Rheumatol Rep. 2017;19(12):78. doi: 10.1007/s11926-017-0707-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-017-0707-z</ArticleId><ArticleId IdType="pubmed">29101479</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrada AA, Escobedo N, Iruretagoyena M, et al. Innate immune cells&#x2019; contribution to systemic lupus erythematosus. Front Immunol. 2019;10:772. doi: 10.3389/fimmu.2019.00772</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00772</ArticleId><ArticleId IdType="pmc">PMC6476281</ArticleId><ArticleId IdType="pubmed">31037070</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco P, Palucka A, Pascual V, et al. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008;19(1):41&#x2013;52. doi:10.1016/j.cytogfr.2007.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2007.10.004</ArticleId><ArticleId IdType="pmc">PMC2413068</ArticleId><ArticleId IdType="pubmed">18258476</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson U, Ricci R, Hunziker L, et al. Dendritic cell&#x2013;induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med. 2003;9(12):1484&#x2013;1490. doi:10.1038/nm960</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm960</ArticleId><ArticleId IdType="pubmed">14625544</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell GM, Anderson AE, Diboll J, et al. Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Ann Rheum Dis. 2017;76(1):227&#x2013;234. doi:10.1136/annrheumdis-2015-208456</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-208456</ArticleId><ArticleId IdType="pmc">PMC5264217</ArticleId><ArticleId IdType="pubmed">27117700</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips BE, Garciafigueroa Y, Engman C, et al. Tolerogenic dendritic cells and T-Regulatory cells at the clinical trials crossroad for the treatment of autoimmune disease; emphasis on type 1 diabetes therapy. Front Immunol. 2019;10:148. doi: 10.3389/fimmu.2019.00148</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00148</ArticleId><ArticleId IdType="pmc">PMC6372505</ArticleId><ArticleId IdType="pubmed">30787930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding D, Mehta H, McCune WJ, et al. Aberrant phenotype and function of myeloid dendritic cells in systemic lupus erythematosus. J Immunol. 2006;177(9):5878&#x2013;5889. doi:10.4049/jimmunol.177.9.5878</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.9.5878</ArticleId><ArticleId IdType="pubmed">17056512</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Liang J, Qin H, et al. Elevated expression of miR-142-3p is related to the pro-inflammatory function of monocyte-derived dendritic cells in SLE. Arthritis Res Ther. 2016;18(1):263. doi:10.1186/s13075-016-1158-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-1158-z</ArticleId><ArticleId IdType="pmc">PMC5112667</ArticleId><ArticleId IdType="pubmed">27852285</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem. 2012;81(1):145&#x2013;166. doi: 10.1146/annurev-biochem-051410-092902</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-051410-092902</ArticleId><ArticleId IdType="pmc">PMC3858397</ArticleId><ArticleId IdType="pubmed">22663078</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu L, Lou F, Sun Y, et al. A micropeptide encoded by lncRNA MIR155HG suppresses autoimmune inflammation via modulating antigen presentation. Sci Adv. 2020;6(21):eaaz2059. doi:10.1126/sciadv.aaz2059</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz2059</ArticleId><ArticleId IdType="pmc">PMC7314557</ArticleId><ArticleId IdType="pubmed">32671205</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Xue Y, Han Y, et al. The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. Science. 2014;344(6181):310&#x2013;313. doi:10.1126/science.1251456</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1251456</ArticleId><ArticleId IdType="pubmed">24744378</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Zhang X, Chen K, et al. CCR7 chemokine receptor-inducible lnc-Dpf3 restrains dendritic cell migration by inhibiting HIF-1&#x3b1;-mediated glycolysis. Immunity. 2019;50(3):600&#x2013;615.e15. doi:10.1016/j.immuni.2019.01.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.01.021</ArticleId><ArticleId IdType="pubmed">30824325</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the rosetta stone of a hidden RNA language? Cell. 2011;146(3):353&#x2013;358. doi:10.1016/j.cell.2011.07.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.07.014</ArticleId><ArticleId IdType="pmc">PMC3235919</ArticleId><ArticleId IdType="pubmed">21802130</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Chen S, Chen S, et al. Long noncoding RNA expression profile and association with SLEDAI score in monocyte-derived dendritic cells from patients with systematic lupus erythematosus. Arthritis Res Ther. 2018;20(1):138. doi:10.1186/s13075-018-1640-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-018-1640-x</ArticleId><ArticleId IdType="pmc">PMC6042324</ArticleId><ArticleId IdType="pubmed">29996948</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Li J, Chen C, et al. Pan-cancer analysis of long non-coding RNA NEAT1 in various cancers. Genes Dis. 2018;5(1):27&#x2013;35. doi:10.1016/j.gendis.2017.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gendis.2017.11.003</ArticleId><ArticleId IdType="pmc">PMC6146416</ArticleId><ArticleId IdType="pubmed">30258932</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Cao L, Zhou R, et al. The lncRNA Neat1 promotes activation of inflammasomes in macrophages. Nat Commun. 2019;10(1):1495. doi:10.1038/s41467-019-09482-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09482-6</ArticleId><ArticleId IdType="pmc">PMC6445148</ArticleId><ArticleId IdType="pubmed">30940803</ArticleId></ArticleIdList></Reference><Reference><Citation>Waeckerle-Men Y, Scandella E, Allmen E, et al. Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. J Immunol Methods. 2004;287(1&#x2013;2):109&#x2013;124. doi:10.1016/j.jim.2004.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2004.01.010</ArticleId><ArticleId IdType="pubmed">15099760</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin H, Laborel-Pr&#xe9;neron E, Fraysse F, et al. Aquaphilus dolomiae extract counteracts the effects of cutaneous S. aureus secretome isolated from atopic children on CD4 + T cell activation. Pharm Biol. 2016;54(11):2782&#x2013;2785. doi:10.3109/13880209.2016.1173069</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13880209.2016.1173069</ArticleId><ArticleId IdType="pubmed">27180655</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaban A, Leira EC. Neurological complications in patients with systemic lupus erythematosus. Curr Neurol Neurosci Rep. 2019;19(12):97. doi: 10.1007/s11910-019-1012-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-019-1012-1</ArticleId><ArticleId IdType="pubmed">31773306</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed A, Chen Y, Wu H, et al. Therapeutic advances in the treatment of SLE. Int Immunopharmacol. 2019;72:218&#x2013;223. doi: 10.1016/j.intimp.2019.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2019.03.010</ArticleId><ArticleId IdType="pubmed">31002998</ArticleId></ArticleIdList></Reference><Reference><Citation>Oon S, Wilson NJ, Wicks I. Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin Transl Immunol. 2016;5(5):e79. doi: 10.1038/cti.2016.26</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cti.2016.26</ArticleId><ArticleId IdType="pmc">PMC4910120</ArticleId><ArticleId IdType="pubmed">27350879</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathias LM, Stohl W. Systemic lupus erythematosus (SLE): emerging therapeutic targets. Expert Opin Ther Targets. 2020;24(12):1283&#x2013;1302. doi: 10.1080/14728222.2020.1832464</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2020.1832464</ArticleId><ArticleId IdType="pubmed">33034541</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6(6):339&#x2013;347. doi: 10.1038/nrrheum.2010.64</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2010.64</ArticleId><ArticleId IdType="pubmed">20440285</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141(2):125&#x2013;139. doi:10.1016/j.pharmthera.2013.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2013.09.004</ArticleId><ArticleId IdType="pubmed">24076269</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S, Yu C, Yu B. Changes of serum IL-6, IL-10 and TNF-&#x3b1; levels in patients with systemic lupus erythematosus and their clinical value. Am J Transl Res. 2021;13(4):2867&#x2013;2874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8129414</ArticleId><ArticleId IdType="pubmed">34017450</ArticleId></ArticleIdList></Reference><Reference><Citation>Talaat RM, Mohamed SF, Bassyouni IH, et al. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine. 2015;72(2):146&#x2013;153. doi:10.1016/j.cyto.2014.12.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2014.12.027</ArticleId><ArticleId IdType="pubmed">25647269</ArticleId></ArticleIdList></Reference><Reference><Citation>Jego G, Palucka AK, Blanck J-P, et al. Plasmacytoid dendritic cells induce plasma cell differentiation through Type I interferon and interleukin 6. Immunity. 2003;19(2):225&#x2013;234. doi:10.1016/S1074-7613(03)00208-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(03)00208-5</ArticleId><ArticleId IdType="pubmed">12932356</ArticleId></ArticleIdList></Reference><Reference><Citation>Cash H, Relle M, Menke J, et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL- Fas lpr mice: the iL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol. 2010;37(1):60&#x2013;70. doi:10.3899/jrheum.090194</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.090194</ArticleId><ArticleId IdType="pubmed">19955044</ArticleId></ArticleIdList></Reference><Reference><Citation>Katkam SK, Rajasekhar L, Kumaraswami K, et al. Association of IL - 6 -174 G&gt;C polymorphism with the risk of SLE among south Indians: evidence from case&#x2013;control study and meta-analysis. Lupus. 2017;26:1491&#x2013;1501. doi: 10.1177/0961203317711010</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317711010</ArticleId><ArticleId IdType="pubmed">28530463</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards HB, Satoh M, Shaw M, et al. Interleukin 6 dependence of Anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med. 1998;188(5):985&#x2013;990. doi:10.1084/jem.188.5.985</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.188.5.985</ArticleId><ArticleId IdType="pmc">PMC2213386</ArticleId><ArticleId IdType="pubmed">9730900</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung J-Y, Kim M-Y, Suh C-H, et al. Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review. Pediatr Rheumatol. 2018;16(1):79. doi:10.1186/s12969-018-0296-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12969-018-0296-z</ArticleId><ArticleId IdType="pmc">PMC6295005</ArticleId><ArticleId IdType="pubmed">30547812</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott LJ. Tocilizumab: a review in rheumatoid arthritis. Drugs. 2017;77(17):1865&#x2013;1879. doi: 10.1007/s40265-017-0829-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-017-0829-7</ArticleId><ArticleId IdType="pmc">PMC5736769</ArticleId><ArticleId IdType="pubmed">29094311</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317&#x2013;328. doi:10.1056/NEJMoa1613849</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1613849</ArticleId><ArticleId IdType="pubmed">28745999</ArticleId></ArticleIdList></Reference><Reference><Citation>Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542&#x2013;552. doi:10.1002/art.27221</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27221</ArticleId><ArticleId IdType="pmc">PMC3057537</ArticleId><ArticleId IdType="pubmed">20112381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirooka Y, Okuda S, Sugiyama M, et al. Case report: a rare case of elderly-onset adult-onset still&#x2019;s disease in a patient with systemic lupus erythematosus. Front Immunol. 2022;13:822169. doi: 10.3389/fimmu.2022.822169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.822169</ArticleId><ArticleId IdType="pmc">PMC8803898</ArticleId><ArticleId IdType="pubmed">35116046</ArticleId></ArticleIdList></Reference><Reference><Citation>De Matteis A, Sacco E, Celani C, et al. Tocilizumab for massive refractory pleural effusion in an adolescent with systemic lupus erythematosus. Pediatr Rheumatol. 2021;19(1):144. doi:10.1186/s12969-021-00635-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12969-021-00635-w</ArticleId><ArticleId IdType="pmc">PMC8444491</ArticleId><ArticleId IdType="pubmed">34530845</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17(5):272&#x2013;283. doi: 10.1038/nrg.2016.20</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg.2016.20</ArticleId><ArticleId IdType="pubmed">27040487</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamura S, Imai-Sumida M, Tanaka Y, et al. Interaction and cross-talk between non-coding RNAs. Cell Mol Life Sci. 2018;75(3):467&#x2013;484. doi:10.1007/s00018-017-2626-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-017-2626-6</ArticleId><ArticleId IdType="pmc">PMC5765200</ArticleId><ArticleId IdType="pubmed">28840253</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Sun M, Nie F, et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer. 2014;13(1):92. doi:10.1186/1476-4598-13-92</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-4598-13-92</ArticleId><ArticleId IdType="pmc">PMC4021402</ArticleId><ArticleId IdType="pubmed">24775712</ArticleId></ArticleIdList></Reference><Reference><Citation>Imig J, Brunschweiger A, Br&#xfc;mmer A, et al. MiR-CLIP capture of a miRNA targetome uncovers a lincRNA H19&#x2013;miR-106a interaction. Nat Chem Biol. 2015;11(2):107&#x2013;114. doi:10.1038/nchembio.1713</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1713</ArticleId><ArticleId IdType="pubmed">25531890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Liu X, Wu H, et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010;38(16):5366&#x2013;5383. doi:10.1093/nar/gkq285</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq285</ArticleId><ArticleId IdType="pmc">PMC2938198</ArticleId><ArticleId IdType="pubmed">20423907</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond CS, Fox AH. Paraspeckles: nuclear bodies built on long noncoding RNA. J Cell Bio. 2009;186(5):637&#x2013;644. doi: 10.1083/jcb.200906113</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200906113</ArticleId><ArticleId IdType="pmc">PMC2742191</ArticleId><ArticleId IdType="pubmed">19720872</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Hou L, Yuan X, et al. LncRNA NEAT1 targets fibroblast-like synoviocytes in rheumatoid arthritis via the miR-410-3p/YY1 axis. Front Immunol. 2020;11:1975. doi: 10.3389/fimmu.2020.01975</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01975</ArticleId><ArticleId IdType="pmc">PMC7485383</ArticleId><ArticleId IdType="pubmed">32983133</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Wu L, Qian J, et al. Identification of the long noncoding RNA NEAT1 as a novel inflammatory regulator acting through MAPK pathway in human lupus. J Autoimmun. 2016;75:96&#x2013;104. doi: 10.1016/j.jaut.2016.07.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2016.07.012</ArticleId><ArticleId IdType="pubmed">27481557</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>